Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)
Raltegravir is the preferred INSTI for for treatment of antiretroviral-naïve pregnant women in the US Perinatal Guidelines, alongside Dolutegravir, and for late pregnancy. There are relatively limited information available on its use during early pregnancy, particularly the peri-conception period. The aim of the study is to assess "real-world" maternal, fetal and newborn outcomes following RAL use during pregnancy through pooled analysis of individual patient data from observational studies participating in the European Pregnancy and Paediatric Infections Cohort Collaboration.
Multi-centre EuRopean study of Major Infectious Disease Syndromes - PREPARE PED-MERMAIDS
Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial - Neomero2
100 项与 Fondazione Penta Onlus 相关的临床结果
0 项与 Fondazione Penta Onlus 相关的专利(医药)
100 项与 Fondazione Penta Onlus 相关的药物交易
100 项与 Fondazione Penta Onlus 相关的转化医学